Coherus Oncology dismisses EY, names PwC as new auditor

Coherus Oncology, Inc.

CHRS

0.00

Coherus Oncology’s audit committee dismissed Ernst & Young as independent auditor, effective June 12, 2026.
PwC was selected as the new auditor for the fiscal year ending Dec. 31, 2026, subject to standard client acceptance.
EY audit reports for 2025 and 2024 carried no adverse opinion, disclaimer, or qualification.
No accounting or audit-scope disputes were reported with EY through June 12, 2026.
A previously disclosed 2024 material weakness tied to inventory reconciliation documentation was reported remediated in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-074090), on June 15, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.